MA43571A - Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations - Google Patents
Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisationsInfo
- Publication number
- MA43571A MA43571A MA043571A MA43571A MA43571A MA 43571 A MA43571 A MA 43571A MA 043571 A MA043571 A MA 043571A MA 43571 A MA43571 A MA 43571A MA 43571 A MA43571 A MA 43571A
- Authority
- MA
- Morocco
- Prior art keywords
- dkk2
- cysteine
- proteins containing
- field rich
- rich
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387116P | 2015-12-23 | 2015-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43571A true MA43571A (fr) | 2018-11-14 |
Family
ID=57794355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043571A MA43571A (fr) | 2015-12-23 | 2016-12-16 | Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20200270335A1 (fr) |
| EP (1) | EP3394265A1 (fr) |
| MA (1) | MA43571A (fr) |
| WO (1) | WO2017112549A1 (fr) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| CN101951954A (zh) * | 2007-11-02 | 2011-01-19 | 诺瓦提斯公司 | 调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法 |
| WO2010075194A1 (fr) | 2008-12-22 | 2010-07-01 | St. Jude Children's Research Hospital | Expression procaryote de dkk soluble active |
| CN102741280B (zh) | 2009-10-30 | 2015-12-02 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| JP2013519392A (ja) | 2010-02-16 | 2013-05-30 | メディミューン,エルエルシー | Hsa関連組成物および使用方法 |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| MX353816B (es) | 2011-05-05 | 2018-01-30 | Albumedix As | Variantes de albumina. |
| WO2016126054A1 (fr) * | 2015-02-04 | 2016-08-11 | (주)메드팩토 | Composition pour prévenir ou traiter un trouble de l'érection comprenant une protéine dkk2 modifiée ou un gène pour celle-ci, et son procédé d'utilisation |
-
2016
- 2016-12-16 MA MA043571A patent/MA43571A/fr unknown
- 2016-12-16 US US16/063,423 patent/US20200270335A1/en not_active Abandoned
- 2016-12-16 EP EP16825950.5A patent/EP3394265A1/fr not_active Withdrawn
- 2016-12-16 WO PCT/US2016/067335 patent/WO2017112549A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20200270335A1 (en) | 2020-08-27 |
| EP3394265A1 (fr) | 2018-10-31 |
| WO2017112549A1 (fr) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| EP3581651A4 (fr) | Anticorps anti-gprc5d et molécule le contenant | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3375796A4 (fr) | Copolymère et composition le contenant | |
| EP3328895A4 (fr) | Anticorps anti-pd-l1 et leurs utilisations | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| MA43551A (fr) | Protéines immunomodulatrices à variants du ligand icos et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP3710067A4 (fr) | Domaine d contenant des polypeptides et utilisations associées | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3380100A4 (fr) | Inhibiteurs de bromodomaines bivalents et leurs utilisations | |
| EP2953457A4 (fr) | Inhibiteurs d'erk et leurs utilisations | |
| EP3307766A4 (fr) | Protéine d'interleukine-7 modifiée et ses utilisations | |
| EP3344624A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3364958A4 (fr) | Modulateurs d'interaction sestrine-gator2 et leurs utilisations | |
| EP3341007A4 (fr) | Inhibiteurs de malt1 et leurs utilisations |